BioCentury
ARTICLE | Clinical News

SciClone discontinues SCV-07 for HCV

December 16, 2010 1:05 AM UTC

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) discontinued development of SCV-07 to treat HCV after it missed the primary endpoint of a 2 log10 copies/mL reduction in viral load from baseline to week eight in a Phase IIb trial. The trial enrolled 40 non-cirrhotic patients with chronic HCV genotype 1 infection who have relapsed after at least 44 weeks of treatment with Pegasys peginterferon alfa-2a and Copegus ribavirin. SciClone said it will continue development of the synthetic peptide immune stimulant to prevent oral mucositis (OM) in patients with head and neck cancer and plans to start a Phase IIb trial for the indication early next year. ...